Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.51 |
| ▸ | KIT | P10721 | 6/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | NRAS | P01111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376212 | 1.00 | FLT3 (0.51) | FLT3KITIGF1RKDRCSF1R | |
| SCHEMBL10239879 | 0.77 | FLT3 (0.60) | FLT3KITKDRCSF1RIRAK4 | |
| SCHEMBL376585 | 0.77 | FLT3 (0.68) | FLT3KDRIRAK4NRAS | |
| SCHEMBL10239508 | 0.76 | FLT3 (0.58) | FLT3KITKDRCSF1RIRAK4 | |
| SCHEMBL10239837 | 0.76 | FLT3 (0.55) | FLT3KITIGF1RKDRCSF1R | |
| SCHEMBL376164 | 0.76 | FLT3 (0.66) | FLT3KDRCSF1RIRAK4NRAS | |
| SCHEMBL24975663 | 0.75 | FLT3 (0.62) | FLT3KITIGF1RKDRCSF1R | |
| SCHEMBL12553383 | 0.75 | FLT3 (0.55) | FLT3KITIGF1RKDRCSF1R | |
| SCHEMBL24977141 | 0.75 | FLT3 (0.57) | FLT3KITKDRCSF1RIRAK4 | |
| SCHEMBL27362520 | 0.75 | FLT3 (0.57) | FLT3KITKDRCSF1RIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | FLT3 496/4885KIT 324/4885IGF1R 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.